Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 5Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Rhabdoid Tumor 3Prostatic Neoplasms 3Lymphoma, B-Cell 3Wilms Tumor 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, T-Cell 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Tertiary Lymphoid Structures 1Solid Tumor 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neurofibrosarcoma 1Nerve Sheath Neoplasms 1

Interventions

tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inhibition, Psychological × tazemetostat × 90 days × Clear all
NCT04917042 2026-06-04

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

University of Florida

Phase 2 Active not recruiting
10 enrolled 12 charts
Sarcoma

Inhibition, Psychological, Sarcoma, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡